Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: There is growing interest in the identification of novel therapeutic agents for the treatment of affective disorders, with modafinil being one promising substance. The purpose of the present investigation was to compare the efficacy of a combination of fluoxetine plus modafinil with that of fluoxetine plus placebo in the treatment of major depression in a 6-week double blind and placebo-controlled trial. METHODS: Forty-six adult outpatients who met the DSM-IV-TR criteria for major depression participated in the trial. Patients had a baseline Hamilton Rating Scale for depression score of at least 18. Patients were allocated in a random fashion, 23 to fluoxetine 40 mg/day plus modafinil 400 mg/day (200 mg bid) (morning and evening) and 23 to fluoxetine 40 mg/day plus placebo. Patients were assessed at baseline and after 1, 2, 4, and 6 weeks after start of medication. RESULTS: Forty-four patients completed the trial. Fluoxetine+modafinil and fluoxetine+placebo significantly decreased the Hamilton Rating Scale score for Depression over the trial period. However, the combination of fluoxetine and modafinil was significantly superior over fluoxetine alone in the treatment of symptoms of major depression. The difference between the two treatments was significant as indicated by the effect of group, the between-subjects factor (df = 1, F = 4.42, P = 0.046). There were no significant differences in the two groups in terms of observed side-effects. CONCLUSION: These findings suggest modafinil as a well-tolerated and potentially effective agent in combination with fluoxetine in the management of patients with major depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Akhondzadeh, S., Jafari, S., Raisi, F., Nasehi, A. A., Ghoreishi, A., Salehi, B., Mohebbi-Rasa, S., Raznahan, M., & Kamalipour, A. (2009) · Depression and Anxiety · doi:10.1002/da.20589 · Cited by 397
Self-citationA Prospective Trial of Modafinil as an Adjunctive Treatment of Major Depression
DeBattista, C., Lembke, A., Solvason, H. B., Ghebremichael, R., & Poirier, J. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000104910.75206.b9 · Cited by 144 · cited 1×
“They reported that modafinil may be a useful and a well-tolerated adjunctive agent to standard antidepressants in the treatment of major depression.[24] A second placebo-controlled study of 311 patients with MDD who continued to experience excessive sleepiness and fatigue despite adequate SSRI monotherapy reported tha…”
BackgroundKahbazi, M., Ghoreishi, A., Rahiminejad, F., Mohammadi, M.-R., Kamalipour, A., & Akhondzadeh, S. (2009) · Psychiatry Research · doi:10.1016/j.psychres.2008.06.024 · Cited by 91
Self-citationAmiri, S., Mohammadi, M.-R., Mohammadi, M., Nouroozinejad, G.-H., Kahbazi, M., & Akhondzadeh, S. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.07.025 · Cited by 82 · cited 1×
“[8] Although the mechanism of action is not fully understood, modafinil seems to alter the balance of g-aminobutyric acid and glutamate, resulting in the activation of the hypothalamus.[7,9,10] It also increases metabolic rate in the centrolateral thalamus, the central nucleus of the amygdala, and the hippocampus.”
BackgroundSelf-citationThe future of psychopharmacology of depression.
Chang, T., & Fava, M. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06223blu · Cited by 50 · cited 1×
“Although options for pharmacologic treatment have expanded significantly in the past 20 years, between one- and two-thirds of patients will not respond to the first antidepressant prescribed, and 15–33% will not respond to multiple interventions.[22] Patients suffering from treatment-resistant depression (TRD) experie…”
Background
Cited by
Köhler, O., Benros, M. E., Nordentoft, M., Farkouh, M. E., Iyengar, R. L., Mors, O., & Krogh, J. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1611 · Cited by 941
Snyder, H. R., Miyake, A., & Hankin, B. L. (2015) · Frontiers in Psychology · doi:10.3389/fpsyg.2015.00328 · Cited by 946
Cognitive Mechanisms of Treatment in Depression
Roiser, J. P., Elliott, R., & Sahakian, B. J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.183 · Cited by 535
Inflammation in Depression and the Potential for Anti-Inflammatory Treatment
Kohler, O., Krogh, J., Mors, O., & Eriksen Benros, M. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666151208113700 · Cited by 516
“Finally, another emerging drug is the anti-epileptic drug modafinil, which has been associated with anti-inflammatory properties [56] and furthermore shown effective antidepressant effects in augmentation strategies for acute depressive episodes, including symptoms of fatigue, in both unipolar and bipolar disorders [6…”
BackgroundHot and cold cognition in depression
Roiser, J. P., & Sahakian, B. J. (2013) · CNS Spectrums · doi:10.1017/s1092852913000072 · Cited by 354
Metadata
- Authors
- Abolfazli, R., Hosseini, M., Ghanizadeh, A., Ghaleiha, A., Tabrizi, M., Raznahan, M., Golalizadeh, M., & Akhondzadeh, S.
- Venue
- Depression and Anxiety
- Publisher
- Hindawi Limited
- Published
- 2011-02-24
- Volume
- 28
- Issue
- 4
- Pages
- 297-302
- ISSN
- 1091-4269 (ISSN-L)
- OpenAlex
- W2038119785
- Cited by
- 60
- References
- 5
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.